COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,542 Articles (22,881 medRxiv, 8,661 bioRxiv)

Most recent first Previous |  Page 3037: Articles 30361-30370  | Next

ACE2 variants underlie interindividual variability and susceptibility to COVID-19 in Italian population
Renieri, A., Benetti, E., Tita, R., Spiga, O., Ciolfi, A., Birolo, G., Bruselles, A., Doddato, G., Giliberti, A., Marconi, C., Musacchia, F., Pippucci, T., Torella, A., Trezza, A., Valentino, F., Baldassarri, M., Brusco, A., Asselta, R., Mirella, B., Furini, S., Seri, M., Nigro, V., Matullo, G., Tartaglia, M., Mari, F., Pinto, A.
10.1101/2020.04.03.20047977 — Posted: 2020-04-06 Discussion: Onsite
Urinalysis, but not blood biochemistry, detects the early renal-impairment in patients with COVID-19
zhou, H., Zhang, Z., Fan, H., Li, J., Li, M., Dong, Y., Guo, W., Lin, L., Kang, Z., Yu, T., Tian, C., Gui, Y., Qin, R., Wang, H., Luo, S., Hu, D.
10.1101/2020.04.03.20051722 — Posted: 2020-04-06
Frequency of testing for COVID 19 infection and the presence of higher number of available beds per country predict outcomes with the infection, not the GDP of the country - A descriptive statistical analysis
GHOSAL, S., Sinha, B., Sengupta, S., Majumder, M.
10.1101/2020.04.01.20047373 — Posted: 2020-04-06 Discussion: Onsite | Offsite
Forecast of the COVID-19 outbreak, collapse of medical facilities, and lockdown effects in Tokyo, Japan
Sugishita, Y., Kurita, J., Sugawara, T., Ohkusa, Y.
10.1101/2020.04.02.20051490 — Posted: 2020-04-06
The potential genetic network of human brain SARS-CoV-2 infection
Lapina, C., Rodic, M., Peschanski, D., MESMOUDI, S.
10.1101/2020.04.06.027318 — Posted: 2020-04-06
CovProfile: profiling the viral genome and gene expressions of SARS-COV2
Yu, Y., Li, Z., Li, Y., Yu, L., Jia, W., Ye, F., Li, S. C.
10.1101/2020.04.05.026146 — Posted: 2020-04-06
Amantadine disrupts lysosomal gene expression; potential therapy for COVID19
Smieszek, S., Przychodzen, B., Polymeropoulos, M. H.
10.1101/2020.04.05.026187 — Posted: 2020-04-05 Discussion: Onsite
Indomethacin has a potent antiviral activity against SARS CoV-2 in vitro and canine coronavirus in vivo
Xu, T., Gao, X., Wu, Z., Selinger, D. W., Zhou, Z.
10.1101/2020.04.01.017624 — Posted: 2020-04-05 Discussion: Onsite
LY6E Restricts the Entry of Human Coronaviruses, including the currently pandemic SARS-CoV-2
Zhao, X., Zheng, S., Chen, D., Zheng, M., Li, X., Li, G., Lin, H., Chang, J., Zeng, H., Guo, J.-T.
10.1101/2020.04.02.021469 — Posted: 2020-04-05
Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production
Fintelman-Rodrigues, N., Sacramento, C. Q., Ribeiro Lima, C., Souza da Silva, F., Ferreira, A., Mattos, M., de Freitas, C. S., Cardoso Soares, V., da Silva Gomes Dias, S., Temerozo, J. R., Miranda, M., Matos, A. R., Bozza, F. A., Carels, N., Roberto Alves, C., Siqueira, M. M., Bozza, P. T., Souza, T. M. L.
10.1101/2020.04.04.020925 — Posted: 2020-04-05 Discussion: Onsite | Offsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).